List of Nityr drug patents

Nityr is owned by Cycle Pharms Ltd.

Nityr contains Nitisinone.

Nityr has a total of 1 drug patent out of which 0 drug patents have expired.

Nityr was authorised for market use on 26 July, 2017.

Nityr is available in tablet;oral dosage forms.

Nityr can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.

The generics of Nityr are possible to be released after 05 January, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328029 CYCLE PHARMS LTD Pharmaceutical composition
Jan, 2035

(11 years from now)

Drugs and Companies using NITISINONE ingredient

Market Authorisation Date: 26 July, 2017

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic